Category Archives: Pharmacy

FDA MedWatch: Pioglitazone-containing Medicines

 

MedWatch – The FDA Safety Information and Adverse Event Reporting Program

Pioglitazone-containing Medicines: Drug Safety Communication – Updated FDA Review, Increased Risk of Bladder Cancer

Includes Actos, Actoplus Met, Actoplus Met XR, Duetact, and Oseni

AUDIENCE: Internal Medicine, Endocrinology, Urology

ISSUE: As a result of an updated review, the FDA has concluded that use of the type 2 diabetes medicine pioglitazone (Actos, Actoplus Met, Actoplus Met XR, Duetact, Oseni) may be linked to an increased risk of bladder cancer. The labels of pioglitazone-containing medicines already contain warnings about this risk, and FDA has approved label updates to describe the additional studies reviewed. See the FDA Drug Safety Communication for more details, including a data summary.

BACKGROUND: FDA alerted the public about the possible risk of bladder cancer in September 2010 and June 2011 based on interim results from a 10-year epidemiologic study. FDA changed the labels of pioglitazone-containing medicines in August 2011 to include warnings about this risk, and required the manufacturer to modify and continue the 10-year study.

Pioglitazone is approved to improve blood sugar control, along with diet and exercise, in adults with type 2 diabetes. Pioglitazone works by increasing the body’s sensitivity to insulin, a natural hormone that helps control blood sugar levels. Untreated, type 2 diabetes can lead to serious problems, including blindness, nerve and kidney damage, and heart disease.

RECOMMENDATION: Health care professionals should not use pioglitazone in patients with active bladder cancer, and should carefully consider the benefits and risks before using pioglitazone in patients with a history of bladder cancer.

Patients should contact their health care professionals if they experience any of the following signs or symptoms after starting pioglitazone, as these may be due to bladder cancer:

  • Blood or a red color in the urine
  • New or worsening urge to urinate
  • Pain when urinating

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program:

  • Complete and submit the report Online: www.fda.gov/MedWatch/report
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

Read the MedWatch safety alert, including a link to the Drug Safety Communication, at:

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm532772.htm

You are encouraged to report all serious adverse events and product quality problems to FDA MedWatch at www.fda.gov/medwatch/report.htm

Follow MedWatch on Twitter

Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your email address to log in. If you have questions or problems with the subscription service, please visit subscriberhelp.govdelivery.com.

This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).

Pharmacy and Therapeutics Newsletter Sept 2016

September 22, 2016 issue
Volume 16, Number 5

Table of contents

Enoxaparin Injection Sites

As we know, administration of subcutaneous enoxaparin (LOVENOX) should be alternated between
the left and right anterolateral and left and right posterolateral abdominal wall. Pharmacy has
received requests for administration to be made in areas such as the thigh. Research into alternate
site administration is limited. Only one study was found which compared enoxaparin administration
into the thigh versus the standard injection site. This study was conducted in obese patients and found
that when enoxaparin was injected into the thigh, anti Xa levels were found to be significantly lower.
Based on this limited information and the inability to monitor in-house anti Xa levels at CHS,
administration at the sites outlined by the manufacturer should be followed.

Formulary Additions

Loxapine Inhalation (ADASUVE) Read more here … pt-newsletter-16-5-092216pt

Formulary Additions for Lurie Pediatric Patients

  1. Ampicillin sulbactam (UNASYN) 1.5 GM for injection – added with pediatric restriction
  2. Cefotaxime (CLAFORAN) 500 mg, 1 GM, 2 GM for injection – added with pediatric restriction
  3. Ibuprofen chewable tablet 50 mg and 100 mg – added for pediatrics
  4. Montelukast (SINGULAR) 5 mg tablet – added for pediatrics
  5. Ranitidine (ZANTAC) 15 mg/mL Syrup – added for pediatrics
  6. Sodium Chloride 3% Nebs – added for pediatrics
    1. Vitamin A & D Ointment – added for pediatrics
  7. Sacchromyces boulardi (FLORASTOR) 250 mg capsule and packet – add for pediatric and adult patients

Formulary Deletions

  1. Alvimopan (ENTEREG) – Pharmacy will maintain supply until current stock expires. If this product has little or no use, it will be removed from formulary.
  2. Lidocaine 5%/D7.5W (PF) 100 mg/2 mL injection
  3. Bupivacaine-dextrose-water (PF) 15 mg/2 mL injection
  4. Heparin 1000 units/mL 30 mL MDV
  5. Tromethamine 36 mg/mL 500 mL solution for injection (THAM) – off market
  6. Sodium polystyrene sulfonate powder 454 GM

Therapeutic Substitutions

Drug Ordered Dispensed With
Acetaminophen IV(OFIRMEV) 650 mg for nonpediatric patients Acetaminophen IV (OFIRMEV) 1000 mg
Zolpidem CR (AMBIEN CR) 12.5 mg or 6.25 mg Zolpidem (AMBIEN) 5 mg
Brinzolamide (AZOPT) Ophthalmic Solution 1 drop tid affected eye(s). Dorzolamide (TRUSOPT) Ophthalmic Solution 1 drop tid affected eye(s).

Policy/Protocol Revision

7300–531PT Medication Order Duration Policy
This policy, which specifies medication order duration based on individual medication or medication class type, had previously been deleted. At the February, 2016 Pharmacy and Therapeutics Committee meeting, it was resurrected so that appropriate durations could be placed in Paragon.
The revision that was made at this time was reorganization to make incorporation into Paragon easier.

7300–621PT Argatroban Dosing and Monitoring per Pharmacy Protocol
This protocol has been used for many years without substantial change. It details Argatroban dosing and dose adjustment when the drug is used for heparin induced thrombocytopenia or heparin induced thrombocytopenia with thrombotic syndrome. The only change that was made at this time regards removal of wording for a paper order.

7300–690PT Pediatric Medication Preparation and Administration
This policy, recognizing that the pediatric population has significant specific needs, an interdisciplinary process is designed to ensure that pediatric medication therapy is prepared and dispensed in a safe, effective, and timely manner and that all medications administered to pediatric patients are given accurately, safely, and with proper technique for each method of administration. The change that was made to this policy was the removal of the 0.1 mL overfill on IM and subcutaneous medications drawn up by Pharmacy.

Current drug shortages now added to this website

Current drug shortages will be available under Clinical-> Pharmacy-> Drug shortages.

The link is also available under quicklinks in the right sidebar for desktop users.

Pharmacy & Therapeutics Newsletter 16.1

Headlines from the February issue of the P&T newsletter.

  • VTE Recurrence
  • Neonatal Preparation and Administration
  • Anti-Infective Medications Limited to the Order by an ID Specialist
  • Amphotericin B Deoxycholate added to the automatic substitution list
  • Injectable Iron Products for Use in the Ambulatory Clinic
  • IdaruCIZUMAB (PRDXBIND) added to the formulary
  • Reduction in Lidocaine Products

PT Newsletter 16.1 11.19.15PT

Pharmacy & Therapeutics Newsletter

PT Newsletter 15.6 091715PT

Pharmacy & Therapeutics Newsletter 15.5

PT Newsletter 15.5 062515PT

Pharmacy & Therapeutics Newsletter 15.2

PT Newsletter 15.2 112014PT